6 Overstated
Marc Schuckit's studies showed that young male children of alcoholic fathers exhibit less measurable body sway after consuming alcohol and experience fewer hangovers the next day compared to control subjects.
"So Marc Schuckit, who's a superb psychiatrist based in Southern California for most of his career, did some wonderful studies of male children of alcoholic fathers. And one of the things he showed is that when given alcohol, their body sway is less at a level you can't even perceive, but he could measure that. And they had fewer hangovers the next day." (said at 0:12:46)
Marc Schuckit's seminal longitudinal research at UCSD demonstrated that young adult sons of alcoholic fathers exhibit a lower level of response (reduced sensitivity) to alcohol challenges compared to control subjects, which includes significantly less increase in measurable body sway (static ataxia), fewer subjective feelings of intoxication, and attenuated hormonal responses (PMID: 3056066, PMID: 1758993, PMID: 1845531). However, the claim that they experience 'fewer hangovers the next day' is inaccurate; Schuckit's research focused on the acute low level of response (LR) rather than fewer hangovers, and external literature on familial risk of alcoholism actually demonstrates either comparable or greater severity of hangover symptoms among sons of alcoholics (PMID: 2264599). Because the claim bundles the well-documented body sway finding with an inaccurate assertion regarding hangovers, it is graded overstated.
- supports: A longitudinal study of children of alcoholics. (Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism 1991) · cited 34x in the literature
"Our laboratory has, however, consistently documented less intense responses to alcohol for the sons of alcoholics, findings consistent across subjective feelings, increases in body sway, and changes in several hormones and electrophysiological measures." (abstract, results, passage verified)
pubmed - supports: A 10-year follow-up of sons of alcoholics: preliminary results. (Alcohol and alcoholism (Oxford, Oxfordshire). Supplement 1991) · cited 11x in the literature
"At the time of initial evaluation, and at an average age of approximately 21 years, the sons of alcoholics demonstrated a diminished response to alcohol as measured by their subjective feelings, levels of body sway, electrophysiological functioning, and changes in 3 hormones." (abstract, results, passage verified)
pubmed - supports: Reactions to alcohol in sons of alcoholics and controls. (Alcoholism, clinical and experimental research 1988) · cited 119x in the literature
"Consistent results corroborated by several additional groups indicate that the higher risk sons of alcoholics demonstrate less intense reactions to ethanol as measured by their subjective self-reports, measures of body sway, changes in several hormones after drinking, and the intensity or persistence of ethanol-related changes on two electrophysiological measures." (abstract, results, passage verified)
pubmedfull study (doi)
There is zero scientific evidence that microdosing psilocybin provides any clinical or cognitive benefit.
"My read of the literature—and this might have been updated since—uh is that there is zero evidence that microdosing psilocybin has any benefit." (said at 1:12:18)
The host's assertion that there is 'zero evidence' is overstated. While observational studies, naturalistic surveys, and open-label reports frequently document perceived improvements in mood, focus, and well-being, rigorous double-blind, placebo-controlled randomized trials have largely failed to find significant cognitive, emotional, or clinical benefits of psilocybin microdosing beyond the placebo effect.
- partial: Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregis… (Journal of psychopharmacology (Oxford, England) 2022) · cited 73x in the literature
"Our confirmatory analyses revealed that psilocybin microdosing did not affect emotion processing or symptoms of anxiety and depression compared with placebo." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. (Translational psychiatry 2022) · cited 137x in the literature
"According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review. (The primary care companion for CNS disorders 2024) · cited 8x in the literature
"There is a growing body of evidence suggesting a positive correlation between psychedelic microdosing and improved mental well-being. However, due to the limited number of controlled studies and the small sample sizes in some of the studies, the causal relationship between microdosing and mental health improvement remains uncertain." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Starting cigarette smoking at age 13 almost certainly results in addiction, whereas starting at an older age rarely leads to addiction.
"It's also true that if you start smoking cigarettes at my age, you probably will not get addicted, and if you start smoking cigarettes when you're 13, you almost certainly will." (said at 1:22:02)
Extensive epidemiological research demonstrates that early tobacco initiation (at or before age 13) is significantly associated with higher rates and severity of nicotine dependence, heavier smoking, and lower cessation rates compared to later initiation. However, the speaker grossly exaggerates this relative risk gradient into absolute certainties: starting at age 13 does not 'almost certainly' cause addiction (absolute rates of transition to dependence among early experimenters are elevated but well below certainty), and adults initiating regular cigarette smoking remain highly susceptible to nicotine addiction rather than being largely protected.
Nicotine exerts protective effects against Parkinson's disease and Alzheimer's disease.
"Richard Axel at Columbia, who told me long ago and many times nicotine is protective against Parkinson's and Alzheimer's" (said at 1:45:18)
The claim is overstated. Decades of epidemiological data show an inverse association between tobacco use and the risk of developing Parkinson's disease, and preclinical laboratory studies demonstrate neuroprotective effects of nicotine via nicotinic acetylcholine receptors. However, translation to humans has not demonstrated disease-modifying or neuroprotective efficacy. A major Phase 2 randomized, double-blind, placebo-controlled trial (the NIC-PD study, PMID 38320207) found that 52 weeks of transdermal nicotine did not slow disease progression in early Parkinson's disease. For Alzheimer's disease, smoking is generally associated with increased risk, though pure nicotinic agonists have shown modest, transient symptomatic effects on attention rather than proven neuroprotection.
- contradicts: Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease. (NEJM evidence 2023) · cited 27x in the literature
"Epidemiologic studies show that smokers have a lower incidence of Parkinson's disease. Nicotine has been hypothesized to slow progression in early Parkinson's disease... One-year transdermal nicotine treatment did not slow progression in early Parkinson's disease." (abstract, background and conclusions)
pubmedfull study (doi) - partial: Significance of nicotine and nicotinic acetylcholine receptors in Parkinson's disease. (Frontiers in aging neuroscience 2025) · cited 16x in the literature
"We elucidate the relationship between smoking and the reduced risk of PD, highlighting the potential neuroprotective effects of nicotine present in tobacco. The interaction between nicotine and nicotinic acetylcholine receptors (nAChRs) is analyzed in detail, emphasizing their neuroprotective capabilities and underlying molecular mechanisms." (abstract, passage verified)
pubmedfull study (doi) - partial: Nicotine in Neurodegenerative and Neuropsychiatric Disorders: Mechanisms and Clinical Evid… (Neurochemical research 2026)
"Acting predominantly through nicotinic acetylcholine receptors, nicotine influences multiple neurotransmitter systems, modulates neuroinflammation, and supports synaptic plasticity. These mechanisms may be therapeutically relevant in disorders characterized by neurodegeneration or disrupted neurocircuitry, including Parkinson's disease, Alzheimer's disease" (abstract, passage verified)
pubmedfull study (doi)
A Cochrane Collaboration review found that Alcoholics Anonymous and 12-step facilitation counseling produced roughly 50% higher rates of continuous abstinence from alcohol compared to therapies like cognitive behavioral therapy and motivational enhancement therapy.
"And so finally a few years ago, me, John Kelly, and Marica Ferri did what's called a Cochrane Collaboration uh review... On abstinence outcomes, if you ask like, do people stop entirely? AA and also 12-step facilitation kinds of counseling to help people get into AA was winning, you know, by 50% higher rates routinely of that." (said at 2:33:11)
The 2020 Cochrane systematic review co-authored by Kelly, Humphreys, and Ferri found high-certainty evidence that manualized Alcoholics Anonymous and Twelve-Step Facilitation (AA/TSF) interventions were superior to other active psychological treatments (such as CBT and MET) for continuous alcohol abstinence. However, the pooled effect size at 12 months was a 21% increase in continuous abstinence rates (RR 1.21, 95% CI 1.03 to 1.42), making the claim of '50% higher rates routinely' an overstatement of the meta-analytic findings.
The male-to-female ratio for opioid addiction is approximately four men to every one woman.
"You know, opioids probably four men to every one woman" (said at 3:18:55)
While men consistently have higher rates of opioid use disorder and opioid overdose deaths than women, national epidemiologic data show a male-to-female ratio closer to 1.5:1 to 2:1, not 4:1. For example, large-scale analyses of US national mortality data indicate a male-to-female opioid mortality rate ratio of approximately 2.11, and national survey data on substance use disorders find that roughly 63% of individuals with substance use disorders are male (~1.7:1). Stating that the ratio is 'probably four men to every one woman' substantially overstates the gender gap.
- contradicts: Need for and Receipt of Substance Use Disorder Treatment Among Adults, by Gender, in the U… (Public health reports (Washington, D.C. : 1974) 2022) · cited 42x in the literature
"Among adults with a past-year SUD, 63.4% were men and 36.6% were women ( P < .001), only 10.6% received SUD treatment, and a greater percentage of women than men needed treatment for opioid use disorder (11.9% vs 9.9%; P = .002)." (abstract, results)
pubmedfull study (doi) - contradicts: Sex Differences in Opioid-Related Mortality Trends in the United States, 1999-2020: By Age… (Journal of women's health (2002) 2025) · cited 2x in the literature
"Men experienced a significantly higher mortality burden than women (mortality rate ratio = 2.11; 95% CI: 2.09, 2.12)." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.